Met Life Investment Management, LLC Stoke Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $14.7 Billion
- Q1 2024
A detailed history of Met Life Investment Management, LLC transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 8,284 shares of STOK stock, worth $106,283. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,284Holding current value
$106,283% of portfolio
0.0%Shares
29 transactions
Others Institutions Holding STOK
# of Institutions
111Shares Held
50MCall Options Held
63KPut Options Held
111K-
Skorpios Trust14.4MShares$185 Million99.92% of portfolio
-
Redmile Group, LLC San Francisco, CA5.07MShares$65.1 Million2.7% of portfolio
-
Rtw Investments, LP New York, NY4.22MShares$54.2 Million0.92% of portfolio
-
Morgan Stanley New York, NY4.03MShares$51.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.86MShares$49.5 Million0.0% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $506M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...